CRISPR Therapeutics Stock News

CRISPR Therapeutics' first gene-editing candidate is moving closer to the finish line. An FDA advisory meeting this week set a positive tone ahead of a big regulatory decision.

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri

Stocks are up today as investors prepare for the latest information from the Federal Reserve concerning interest rates. The Federal Open Market Committee (FOMC) meeting taking place today will result

After being halted yesterday during the deliberations of a Food and Drug Administration (FDA) advisory committee, CRISPR Therapeutics (NASDAQ: CRSP ) stock is rallying 5% today in early trading. That

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.

Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.

Among the more prominent gene-editing stocks on the market, investors in this space pay particularly close attention to CRISPR Therapeutics (NASDAQ: CRSP ). That's due to the fact that CRISPR is among

Shares of genetic engineering specialist CRISPR Therapeutics (NASDAQ: CRSP ) moved up modestly on Friday as stakeholders await a final regulatory decision regarding a key therapeutic. Earlier, CRISPR

CRISPR Therapeutics may soon launch its first approved product. The economic environment has weighed on Etsy, but recent trends show growth may be reaccelerating.

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

The potential for CRISPR Therapeutics' pipeline is tremendous. However, an expected product approval may not offer the stock a huge lift.

Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.

Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia,

Superstar investor Wood looks for innovators whose products could be game changers down the road. She goes for companies that are undervalued today considering their long-term potential.

There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its